Effects of the use of semaglutide as a pharmacological option for weight loss in adults with BMI > 25 Kg/m²: a scoping review





Adult; Glucagon-like peptide 1; Obesity.


Introduction: Obesity is a chronic disease resulting from the functional metabolic impairment of the body, whose main consequence is secondary cardiovascular diseases, presenting, therefore, overweight as a risk factor in adults. Therefore, it became essential to search for a pharmacological approach to help change eating habits and routine physical activities, in order to minimize the chances of development and recurrence of the disease. Objective: to evaluate the drug potential of semaglutide as an adjuvant therapy for weight loss in adults who demonstrate body mass index values ​​above 25. Methodology: this is a Scope Review, carried out from September to October 2022, through a survey in the MEDLINE database using the Mesh Terms used in the search using the PubMed platform. For the review, 20 articles were selected, which met the eligibility criteria. Results: the main findings evidenced the benefits of the drug for sustained weight loss in obese patients, reduction of cardiometabolic risk and improvement of glycemic control. In addition to natriuretic and diuretic effects, which reduce blood pressure and improve inflammatory processes. Conclusion: although there is no definitive consensus in the scientific community on the possible effects associated with the use of semaglutide, the literature converges in the same direction regarding the consolidation of semaglutide as a promising drug in the weight loss process of overweight and obese adults.


Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I. … Aroda, V. R. (2018). Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes care, 41(2), 258–266.

Arksey, H., & O’Malley, L. (2002). Scoping studies: towards a methodological framework. International Journal of Social Research Methodology, 8(1), 19-32.

Bersoux, S., Byun, T. H., Chaliki, S. S., & Poole, K. G. (2017). Pharmacotherapy for obesity: What you need to know. Cleveland Clinic journal of medicine, 84(12), 951–958.

Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019). Semaglutide as a promising antiobesity drug. Obesity reviews : an official journal of the International Association for the Study of Obesity, 20(6), 805–815.

Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L. … STEP 2 Study Group (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England), 397(10278), 971–984.

Davies, M., Pieber, T. R., Hartoft-Nielsen, M. L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017). Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA, 318(15), 1460–1470.

Davis, E. M., & Sandoval, D. A. (2020). Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function. Comprehensive Physiology, 10(2), 577–595.

Khalil, H., Ellwood, L., Lord, H., & Fernandez, R. (2020). Pharmacological Treatment for Obesity in Adults: An Umbrella Review. The Annals of pharmacotherapy, 54(7), 691–705.

Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in endocrinology, 10, 155.

Levac, D., Colquhoun, H., & O'Brien, K. K. (2010). Scoping studies: advancing the methodology. Implementation science : IS, 5, 69.

Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M. … & Torekov, S. S. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. The New England journal of medicine, 384(18), 1719–1730.

Meier, J. J. (2021). Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Frontiers in endocrinology, 12, 645617.

Nauck, M. A., & Quast, D. R. (2021). Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Frontiers in endocrinology, 12, 645566.

Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C. … STEP 4 Investigators (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425.

Ryan D. H. (2021). Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?. Journal of obesity & metabolic syndrome, 30(3), 196–208.

Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E. … Lincoff, A. M. (2020). Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American heart journal, 229, 61–69.

Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022). Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 70(1), 5–13.

Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in endocrinology, 12, 645563.

Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A. … & STEP 3 Investigators (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403–1413.

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I. … & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002.

Tak, Y. J., & Lee, S. Y. (2021). Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. Current obesity reports, 10(1), 14–30.

von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P. … & STROBE Initiative (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England), 370(9596), 1453–1457.



How to Cite

FREITAS, G. C. P. L. de .; VASCONCELOS, M. C. de H. V. .; BISNETA, A. I. S. .; PARRA, R. L. O. .; PEREIRA, M. E. B. .; NEGREIROS, M. E. L. .; TOLEDO , M. B. .; ALVES, G. C. .; SOBRINHO, F. E. R. A. . Effects of the use of semaglutide as a pharmacological option for weight loss in adults with BMI > 25 Kg/m²: a scoping review. Research, Society and Development, [S. l.], v. 12, n. 4, p. e9012440955, 2023. DOI: 10.33448/rsd-v12i4.40955. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/40955. Acesso em: 29 may. 2023.



Health Sciences